BackgroundEnfortumab vedotin plus pembrolizumab (EV/P) is a promising treatment for metastatic urothelial carcinoma (mUC), but a comprehensive efficacy and safety synthesis is currently lacking.
No takes yet. Share an insight, caveat, or question.
Hemida et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: